Analysis of Randomized Controlled Trials on the Effect of Magnitude of Heart Rate Reduction on Clinical Outcomes in Patients With Systolic Chronic Heart Failure Receiving Beta-Blockers

American Journal of Cardiology

Volumn 101, Issue 6, 2008, Pages 865-869

  Flannery, Genevieve ^a   Gehrig Mills, Rosie ^a,b   Billah, Baki ^b   Krum, Henry ^a,b  

^a ALFRED HOSPITAL   (Australia)

^b NATIONAL HEALTH AND MEDICAL RESEARCH COUNCIL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; CELIPROLOL; ENALAPRIL; METOPROLOL; METOPROLOL SUCCINATE; NEBIVOLOL; PLACEBO;

CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORRELATION ANALYSIS; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HUMAN; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTOLIC HEART FAILURE; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; CAUSE OF DEATH; CHRONIC DISEASE; HEART FAILURE, SYSTOLIC; HEART RATE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE; VICTORIA;

EID: 40149089700     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.11.023     Document Type: Review

References (52)

1. Swedberg K., Cleland J., Dargie H., Drexler H., Follath F., Komajda M., Tavazzi L., Smiseth O.A., Gavazzi A., Haverich A., et al., Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 26 (2005) 1115-1140
2. Hunt S.A., and American College of Cardiology. American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 46 (2005) e1-e82
3. Lechat P., Packer M., Chalon S., Cucherat M., Arab T., and Boissel J.P. Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double blind, placebo controlled, randomized trials. Circulation 98 (1998) 1184-1191
4. Packer M., Antonopoulos G.V., Berlin J.A., Chittams J., Konstam M.A., and Udelson J.E. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. Am Heart J 141 (2001) 899-907
5. BEST Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 344 (2001) 1659-1667
6. CIBIS Investigators. A randomised trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 90 (1994) 1765-1773
7. CIBIS II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomised trial. Lancet 353 (1999) 9-13
8. Lechat P., Hulot J., Escolano S., Mallet A., Leizorovicz A., Werhlen-Grandjean M., Pochmalicki G., Dargie H., and CIBIS II Investigators. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II trial. Circulation 103 (2001) 1428-1433
9. Willenheimer R., van Veldhuisen D., Silke B., Erdmann E., Follath F., Krum H., Ponikowski P., Skene A., van de Ven L., Verkenne P., Lechat P., and CIBIS III Investigators. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence. Results of the randomised Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 112 (2005) 2426-2435
10. Poole-Wilson P., Swedberg K., Cleland J., Di Lenarda A., Hanrath P., Komajda M., Lubsen J., Lutiger B., Metra M., Remme W.J., et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362 (2003) 7-13
11. Packer M., Coats A., Fowler M., Katus H.A., Krum H., Mohacsi P., Rouleau J.L., Tendera M., Castaigne A., Roecker E.B., et al., Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of Carvedilol on Survival in Severe Chronic Heart Failure (COPERNICUS). N Engl J Med 344 (2001) 1651-1658
12. MERIT Investigators. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353 (1999) 2001-2007
13. Flather M., Shibata M., Coats A., et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26 (2005) 215-225
14. Packer M., Bristow M.R., Cohn J.N., Colucci W.S., Fowler M.B., Gilbert E.M., and Shusterman N.H. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 334 (1996) 1349-1355
15. Australia/New Zealand Heart Failure Research Collaborative Group. Effects of carvedilol, a vasodilator-B-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation 92 (1995) 212-218
16. Bristow M.R., Gilbert E.M., Abraham W.T., Adams K.F., Fowler M.B., Hershberger R.E., Kubo S.H., Narahara K.A., Ingersoll H., Krueger S., et al., MOCHA Investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 94 (1996) 2807-2816
17. Cleland J.G.F., Pennell D.J., Ray S.G., Coats A.J., MacFarlane P.W., Murray G.D., Dalle Mule J., Vered Z., Lahiri A., and CHRISTMAS investigators. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. Lancet 362 (2003) 14-21
18. Cohn J.N., Fowler M.B., Bristow M.B., Colucci W.S., Gilbert E.M., Kinhal V., Krueger S.K., Lejemtel T., Narahara K.A., Packer M., et al. Safety and efficacy of carvedilol in severe heart failure. J Card Fail 3 (1997) 173-179
19. Di Lenarda A., Sabbadini G., Salvatore L., Sinagra G., Mestroni L., Pinamonti B., Gregori D., Ciani F., Muzzi A., Klugmann S., and Camerini F. Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. J Am Coll Cardiol 33 (1999) 1926-1934
20. Edes I., Gasior Z., and Wita K. Effects of nebivolol on left ventricular function in elderly patients with chronic heart failure: results of the ENECA study. Eur J Heart Fail 7 (2005) 631-639
21. Eichhorn E.J., Heesch C.M., Barnett J.H., Alvarez L.G., Fass S.M., Grayburn P.A., Hatfield B.A., Marcoux L.G., and Malloy C.R. Effect of metoprolol on myocardial function and energetics in patients with non-ischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 24 (1994) 1310-1320
22. Engelmeier R.S., O'Connell J.B., Walsh R., Rad N., Scanlon P.J., and Gunnar R.M. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomised, placebo-controlled trial. Circulation 72 (1985) 536-546
23. Gilbert E.M., Anderson J.L., Deitchman D., Yanowitz F.G., O'Connell J.B., Renlund D.G., Bartholomew M., Mealey P.C., Larrabee P., and Bristow M.R. Long-term β-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. Am J Med 88 (1990) 223-229
24. Goldstein S., Kennedy H.L., Hall C., Anderson J.L., Gheorghiade M., Gottlieb S., Jessup M., Karlsberg R.P., Friday G., and Haskell L. Metoprolol CR/XL in patients with heart failure: a pilot study examining the tolerability, safety and effect on left ventricular ejection fraction. Am Heart J 138 (1999) 1158-1165
25. Groenning B.A., Nilsson J.C., Sondergaard L., Fritz-Hansen T., Larsson H.B., and Hildebrandt P.R. Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. J Am Coll Cardiol 36 (2000) 2072-2080
26. Guazzi M., Agostoni P., Matturri M., Pontone G., and Guazzi M.D. Pulmonary function, cardiac function, and exercise capacity in a follow-up of patients with congestive heart failure treated with carvedilol. Am Heart J 138 (1999) 460-467
27. Krum H., Sackner-Bernstein J.D., Goldsmith R.L., Kukin M.L., Schwartz B., Penn J., Medina N., Yushak M., Horn E., Katz S.D., et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 92 (1995) 1499-1506
28. Kukin M.L., Kalman J., Charney R.H., Levy D.K., Buchholz-Varley C., Ocampo O.N., and Eng C. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 99 (1999) 2645-2651
29. Kukin M.L., Mannino M.M., Freudenberger R.S., Kalman J., Buchholz-Varley C., and Ocampo O. Hemodynamic comparison of twice daily metoprolol tartrate with once daily metoprolol succinate in congestive heart failure. J Am Coll Cardiol 35 (2000) 45-50
30. Metra M., Nardi M., Giubbini R., and Dei Cas L. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 24 (1994) 1678-1687
31. Metra M., Giubbini R., Nodari S., Boldi E., Modena M.G., and Dei Cas L. Differential effects of β-blockers in patients with heart failure: a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation 102 (2000) 546-551
32. Olsen S.L., Gilbert E.M., Renlund D.G., Taylor D.O., Yanowitz F.D., and Bristow M.R. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol 25 (1995) 1225-1231
33. Packer M., Colucci W.S., Sackner-Bernstein J.D., Liang C.-S., Goldscher D.A., Freeman I., Kukin M.L., Kinhal V., Udelson J.E., Klapholz M., et al., PRECISE Study Group. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. Circulation 94 (1996) 2793-2799
34. Pollock S.G., Lystash J., Tedesco C., Craddock G., and Smucker M.L. Usefulness of bucindolol in congestive heart failure. Am J Cardiol 66 (1990) 603-607
35. The RESOLVD Investigators. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: the randomized evaluation of strategies for left ventricular dysfunction pilot study. Circulation 101 (2000) 378-384
36. Sanderson J.E., Chan S.K.W., Yu C.M., Yeung L.Y., Chan W.M., Raymond K., Chan K.W., and Woo K.S. β blockers in heart failure: a comparison of a vasodilating β blocker with metoprolol. Heart 79 (1998) 86-92
37. Sanderson J.E., Chan S.K.W., Yip G., Yeung L.Y.C., Chan K.W., Raymond K., and Woo K.S. Beta-blockade in heart failure: a comparison of carvedilol with metoprolol. J Am Coll Cardiol 34 (1999) 1522-1528
38. Waagstein F., Bristow M.R., Swedberg K., Camerini F., Fowler M.B., Silver M.A., Gilbert E.M., Johnson M.R., Goss F.G., and Hjalmarson A. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 342 (1993) 1441-1446
39. Wisenbaugh T., Katz I., Davis J., Essop R., Skoularigis J., Middlemost S., Rothlisberger C., Skudicky D., and Sareli P. Long-term (3-month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. J Am Coll Cardiol 21 (1993) 1094-1100
40. Woodley S., Gilbert E., Anderson J., O'Connell J.B., Deitchman D., Yanowitz F.G., Mealey P.C., Volkman K., Renlund D.G., and Menlove R. Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation 84 (1991) 2426-2441
41. Prichard B.N., Cruickshank J.M., and Graham B.R. Beta-adrenergic blocking drugs in the treatment of hypertension. Blood Press 10 (2001) 366-386
42. Johnson J.A., Zineh I., Puckett B.J., McGorray S.P., Yarandi H.N., and Pauly D.F. Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther 74 (2003) 44-52
43. White H.L., de Boer R.A., Maqbool A., Greenwood D., van Veldhuisen D.J., Cuthbert R., Ball S.G., Hall A.S., Balmforth A.J., and MERIT-HF Study Group. An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. Eur J Heart Fail 5 (2003) 463-468
44. Liggett S.B., Mialet-Perez J., Thaneemit-Chen S., Weber S.A., Greene S.M., Hodne D., Nelson B., Morrison J., Domanski M.J., Wagoner L.E., et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A 103 (2006) 11288-11293
45. Wikstrand J., Hjalmarson A., Waagstein F., Fagerberg B., Goldstein S., Kjekshus J., Wedel H., and MERIT-HF Study Group. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF). J Am Coll Cardiol 40 (2002) 491-498
46. Sharpe N., and Doughty R.N. Left ventricular remodelling and improved long-term outcomes in chronic heart failure. Eur Heart J 19 suppl (1998) B36-B39
47. Kalra P.R., Moon J.C., and Coats A.J. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure?. Int J Cardiol 85 (2002) 195-197
48. Krum H. Sympathetic activation and the role of beta-blockers in chronic heart failure. Aust N Z J Med 29 (1999) 418-427
49. Cohn J., Pfeffer M., Rouleau J., Sharpe N., Swedberg K., Straub M., Wiltse C., Wright T., and MOXCON Investigators. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 5 (2003) 659-666
50. I-receptor agonist moxonidine. Clin Sci 110 (2006) 329-336
51. Mulder P., and Thuillez C. Heart rate slowing for myocardial dysfunction/heart failure. Adv Cardiol 43 (2006) 97-105
52. Mulder P., Barbier S., Chagraoui A., Richard V., Henry J.P., Lallemand F., Renet S., Lerebours G., Mahlberg-Gaudin F., and Thuillez C. Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation 109 (2004) 1674-1679